Abstract |
The COVID-19 pandemic has highlighted the need for mucosal vaccines as breakthrough infections, short-lived immune responses and emergence of new variants have challenged the efficacy provided by the first generation of vaccines against SARS-CoV-2 viruses. M2SR SARS-CoV-2, an M2-deleted single-replication influenza virus vector modified to encode the SARS-CoV-2 receptor binding domain, was evaluated following intranasal delivery in a hamster challenge model for protection against Wuhan SARS-CoV-2. An adjuvanted inactivated SARS-CoV-2 whole virus vaccine administered intramuscularly was also evaluated. The intranasal M2SR SARS-CoV-2 was more effective than the intramuscular adjuvanted inactivated whole virus vaccine in providing protection against SARS-CoV-2 challenge. M2SR SARS-CoV-2 elicited neutralizing serum antibodies against Wuhan and Omicron SARS-CoV-2 viruses in addition to cross-reactive mucosal antibodies. Furthermore, M2SR SARS-CoV-2 generated serum HAI and mucosal antibody responses against influenza similar to an H3N2 M2SR influenza vaccine. The intranasal dual influenza/COVID M2SR SARS-CoV-2 vaccine has the potential to provide protection against both influenza and COVID.
|
Authors | Lindsay Hill-Batorski, Richard Bowen, Helle Bielefeldt-Ohmann, Michael J Moser, Sarah M Matejka, David Marshall, Yoshihiro Kawaoka, Gabriele Neumann, Pamuk Bilsel |
Journal | Vaccine
(Vaccine)
Vol. 42
Issue 11
Pg. 2770-2780
(Apr 19 2024)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 38508930
(Publication Type: Journal Article)
|
Copyright | Copyright © 2024. Published by Elsevier Ltd. |
Chemical References |
- Influenza Vaccines
- COVID-19 Vaccines
- Antibodies, Viral
- Antibodies, Neutralizing
- Adjuvants, Immunologic
|
Topics |
- Humans
- Cricetinae
- Influenza, Human
(prevention & control)
- Influenza Vaccines
- COVID-19 Vaccines
- SARS-CoV-2
- Orthomyxoviridae Infections
(prevention & control)
- Influenza A Virus, H3N2 Subtype
- Pandemics
(prevention & control)
- Antibodies, Viral
- COVID-19
(prevention & control)
- Vaccination
- Antibodies, Neutralizing
- Adjuvants, Immunologic
|